
# mRNA-LNP/CDMO


# **Contact:** *dds-cdmo-service@fujifilm.com*





LNP ex vivo use for cell therapies

# A challenge on allogenic CAR T cell manufacturing



TRAC is required

electroporation (EP) method

allogeneic CAR-T manufacturing


KO

In the production of allogeneic CAR-T, knockout (KO) of genes such as


in human primary T cells is conventionally performed with

EP method damages cells and reduces its yield. This is a bottleneck on

TCR-KO by ElectroPoration (EP) High KO ><mark>80%</mark> Low cell yield ~20% EP(-)(+) EP(-)(+)



### Application on gene editing



GMP facility (Toyama)


#### LNP screening in activated T cells.

T cells were transfected RNA 2 ug/million cells with each LNP.

TCR KO rate was examined at 4days after treatment.

# **CDMO** services GMP manufacturing – Facility

# One stop shop CDMO services for mRNA/LNP



#### Seam less scales of the manufacturing





## Fill finish line with isolator

Filling Speed

701F
3,000 vials/hour



Headquarter (Tokyo)

R&D lab (Kanagawa)

\*p<0.05

\*\*\*p<0.01

mark tamine

INP

